Centro Internacional de Estudios Clínicos - CIEC
Centro de investigación en Dermatología y ReumatologíaCalle Manzano 343, Oficina 410-411, Comuna de Recoleta, Región Metropolitana, 8420383
Websitehttp://www.ciec-chile.com/
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Dermatólogo con 15 años de experiencia en Investigación clínica. 
Dermatólogo con 10 años de experiencia en Investigación clínica.
Dermatólogo con 5 años de experiencia en Investigación Clínica
Dermatólogo con 5 años de experiencia en Investigación clínica
Reumatóloga con 5 años de experiencia en Investigación clínica
Dermatólogo con 5 años de experiencia en Investigación clínicaReumatóloga con 5 años de experiencia en Investigación clínica
Reumatóloga con 10 años de experiencia en Investigación clínica
Director Médico - Investigador PrincipalFernando Valenzuela Ahumada
Sub-InvestigadorPablo Santa María
Sub-InvestigadorRaúl De la Fuente
Sub-InvestigadorRoberto Bustos
Sub-InvestigadorKaren Vergara
Sub-InvestigadorNicolás Moya
Sub-InvestigadorSilvana Saavedra
Investigador PrincipalMaría Francisca Bozan
Open studies
Lupus
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST) - AMETHYST - BiogenSee more
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus - SELECT-SLE - AbbVieSee more
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) - Merck Sharp & Dohme LLCSee more
Dermatitis
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis - COAST 1 - SanofiSee more
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor - AQUA - SanofiSee more
Alopecia
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata - Up-AA - AbbVieSee more
Arthritis
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis - SELECT- SWITCH - AbbVieSee more
Interstitial Lung Disease
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) - ATHENA-SSc-ILD - Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)See more
Rare diseases
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) - ATHENA-SSc-ILD - Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)See more
